Turkish Journal of Physical Medicine and Rehabilitation 2021 , Vol 67 , Num 3

Staphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab

İlkay Ergenç 1 ,Canan Şanal Toprak 2 ,Zekaver Odabaşı 3
1 Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey
2 Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
3 Department of Infectious Diseaes, Marmara University School of Medicine, Istanbul, Turkey
DOI : 10.5606/tftrd.2021.8208 Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab. Keywords : Abscess, chest wall, costochondritis, COVID-19, tocilizumab